The World’s First RealTime AI Assistant for Pancreatic EUS, Available for Clinical Use in the UK.

Why It Matters

Improved lesion detection during EUS enables earlier treatment, potentially raising survival rates for pancreatic cancer and standardising diagnostic quality across hospitals.

Key Takeaways

• mAI Companion® got MDR CE Mark, first AI for pancreatic EUS UK
• Trained on >5 million expert‑annotated EUS images from hundreds of videos
• Trial with 57 endoscopists showed higher accuracy and fewer missed lesions
• Real‑time AI acts as second set of eyes, boosting exam confidence
• Rollout across England, Scotland, Wales aims to improve early pancreatic cancer detection

Pulse Analysis

Pancreatic cancer remains a leading cause of cancer mortality, largely because it is often diagnosed at an advanced stage. Endoscopic ultrasound (EUS) offers high‑resolution imaging and targeted biopsy, yet its effectiveness hinges on operator expertise and the ability to spot subtle lesions. As healthcare systems push for earlier detection, AI‑driven decision support tools are emerging as a way to augment clinician skill, reduce variability, and accelerate diagnostic pathways.

The newly approved mAI Companion® represents a milestone in this evolution. Built through a multi‑year partnership between Fannin UK, Medi‑Globe, and the IHU‑Strasbourg research institute, the software was trained on more than five million meticulously annotated EUS frames extracted from hundreds of real‑patient videos. This depth of data allows the algorithm to flag both solid and cystic pancreatic abnormalities in real time, effectively providing a “second set of eyes” during the procedure. A randomized video trial involving 57 endoscopists demonstrated a measurable jump in diagnostic accuracy and a notable drop in missed lesions, underscoring the clinical value of AI augmentation.

Regulatory clearance via the MDR CE Mark not only validates the technology’s safety and performance but also opens the door for widespread adoption across the United Kingdom. Initial deployments in leading hospitals across England, Scotland and Wales aim to standardise EUS quality, accelerate early cancer detection, and ultimately improve patient outcomes. As more institutions integrate AI tools like mAI Companion® into routine practice, the industry can expect a shift toward data‑driven, evidence‑based endoscopy that may set new benchmarks for cancer screening and treatment timelines.